Audrey Bellesoeur

Audrey Bellesoeur

Auto-generated profile, based on publicly available information

Audrey Bellesoeur

Département d'oncologie médicale, institut Curie, 26, rue d'Ulm, 75005 Paris, France; Service de pharmacologie, institut Curie, 35, rue Dailly, 92210 Saint-Cloud, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
ABAudrey Bellesoeur
Audrey Bellesoeur
ECEdith Carton
Edith Carton
JAJerome Alexandre
Jerome Alexandre
FGFrancois Goldwasser
Francois Goldwasser
OHOlivier Huillard
Olivier Huillard
Since 2005, the approved first-line treatment of metastatic renal cell carcinoma consists in tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptors (VEGFRs). Axitinib is an oral second-generation TKI and a potent VEGFR inhibitor with a half maximal inhibitory concentration for the VEGF family receptors 10-fold lower than other TKIs. Axitinib activity in renal cell carcinoma (RCC) patients has been studied in various settings and particularly as second-line treatment. In this setting, axitinib with clinically based dose escalation compared to sorafenib has demonstrated an improvement in progression-free survival in a randomized Phase III trial leading to US Food and Drug Administration approval. In the first-line setting, axitinib failed to demonstrate improved efficacy over sorafenib, but the field of RCC treatment is rapidly changing with novel TKIs as cabozantinib or the emergence of check point inhibitors as nivolumab and the place of axitinib in therapy is therefore challenged. In this review, we focus on axitinib pharmacological and clinical properties in RCC patients and discuss its place in the treatment of patients with RCC.

1 September 2018 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
ABAudrey Bellesoeur
Audrey Bellesoeur
ATAudrey Thomas-Schoemann
Audrey Thomas-Schoemann
MAMarie Allard
Marie Allard
DSDavid M Smadja
David M Smadja
MVMichel Vidal
Michel Vidal
Benoit BlanchetBenoit Blanchet
Benoit Blanchet

1 June 2020 in Current Opinion in Chemical Biology
Verified
Journal Article
Closed access
ABAudrey Bellesoeur
Audrey Bellesoeur
NTNouritza Torossian
Nouritza Torossian
SASebastian Amigorena
Sebastian Amigorena
EREmanuela Romano
Emanuela Romano

15 June 2023 in European Radiology
Verified
Journal Article
Closed access
PDF file
CMCaroline Malhaire
Caroline Malhaire
FSFatine Selhane
Fatine Selhane
MSMarie-Judith Saint-Martin
Marie-Judith Saint-Martin
VCVincent Cockenpot
Vincent Cockenpot
PAPia Akl
Pia Akl
FFFrédérique Frouin
Frédérique Frouin

27 October 2021 in International Journal of Women's Dermatology
Verified
Journal Article
Open access
MSMathilde Saint-Ghislain
Mathilde Saint-Ghislain
CLChloé Levenbruck
Chloé Levenbruck
ABAudrey Bellesoeur
Audrey Bellesoeur
Breast cancer and gynecologic cancers affect >3 million women worldwide each year. With advances in precision medicine, a growing number of targeted therapies have been approved recently, and new therapeutic classes have emerged, including cell cycle inhibitors for hormone receptor positive breast cancer, antibody drug conjugate for human epidermal growth factor receptor 2 positive and triple negative breast cancer, and poly-ADP-ribose polymerase inhibitors for ovarian cancer. This article focuses first on the challenges for health care systems to address the specificities of each emerging targeted therapy and new issues raised by oral antitumor treatments, including individualization of prescriptions, drug–drug interaction assessment, pharmaceutical counseling, patient education, and outpatient management. Then, we provide an overview of the main adverse effects of targeted therapies approved for breast and gynecologic cancers, such as hematologic toxicity of cyclin-dependent kinase 4/6 inhibitors and poly-ADP-ribose polymerase inhibitors, metabolic disorders of phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin inhibitors, and cardiovascular toxicity of agents targeting human epidermal growth factor receptor 2.

24 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CCClelia CHALUMEAU
Clelia CHALUMEAU
MCMatthieu Carton
Matthieu Carton
AEAlexandre Eeckhoutte
Alexandre Eeckhoutte
SBStelly Ballet
Stelly Ballet
AVAnne Vincent-Salomon
Anne Vincent-Salomon
FLFlorence Lerebours
Florence Lerebours
Background: The TOP2A and ERBB2 genes are co-amplified in about 40% of HER2 positive (HER2+) breast cancers. Oral etoposide (VP16), an inhibitor of topoisomerase-II (encoded by TOP2A), has demonstrated clinical activity in metastatic breast cancer (MBC). The benefit of oral VP16 combined with trastuzumab (VP16-T) in HER2+ MBC has not yet been evaluated. Methods: Patients treated at the Institut Curie Hospitals with VP16-T for HER2+ MBC were retrieved by an in silico search. Progression-free survival (PFS), overall survival (OS), response rate, prolonged PFS (defined as at least 6 months), clinical benefit, and toxicity were assessed. The co-amplification of ERBB2 and TOP2A was assessed by shallow whole genome sequencing on tumor tissue whenever available. Results: Forty-three patients received VP16-T after a median number of six prior treatment lines for HER2+ MBC. Median PFS and OS were 2.9 months (95% CI [2.4–4.7]) and 11.3 months (95% CI [8.3–25.0]), respectively. Three patients had a complete response, while 12/40 (30%) experienced clinical benefit. Only three patients stopped treatment for toxicity. Seven (35%) patients displayed a TOP2A/ERBB2 co-amplification. No statistically significant correlation was found between outcome and TOP2A/ERBB2 co-amplification. Conclusion: Our analysis suggests a favorable efficacy and toxicity profile for VP16-T in patients with heavily pretreated HER2+ MBC.